Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
42 words
A vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising an immunogenic amount of a recombinant VP1 capsid protein of an avian polyomavirus and a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
42 words
A vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising an immunogenic amount of a recombinant VP1 capsid protein of an avian polyomavirus and a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
26 words
The vaccine of claim 1, further comprising an adjuvant suitable for use in a bird which is classified as being a member of the Psittaciformes order.
Claim 4
Dependent Claim
22 words
The vaccine of claim 2, wherein the adjuvant is a long chain polydispersed B (1,4) linked mannan polymer interspersed with O-acetylated groups.
Claim 5
Dependent Claim
23 words
The vaccine of claim 2, wherein the adjuvant is a deproteinized highly purified cell wall extract of a non-pathogenic strain of Mycobacterium species.
Claim 6
Dependent Claim
11 words
The vaccine of claim 2, wherein the adjuvant is aluminum hydroxide.
Claim 7
Dependent Claim
24 words
The vaccine of claim 1, wherein the immunogenic amount of the recombinant protein of an avian polyomavirus is between 1.0 mg. and 3 mg.
Claim 8
Dependent Claim
32 words
The vaccine of claim 1, wherein the bird is selected from the group consisting of a macaw, an Amazon parrot, a conure, a cockatoo, a Pionus Parrot, and an African Grey Parrot.
Claim 9
Independent Claim
47 words
A method of preventing avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising administering to the bird a vaccine comprising an immunogenic amount of a recombinant VP1 capsid protein of an avian polyomavirus and a pharmaceutically acceptable carrier.
Claim 10
Independent Claim
47 words
A method of preventing avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising administering to the bird a vaccine comprising an immunogenic amount of a recombinant VP1 capsid protein of an avian polyomavirus and a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
28 words
The method of claim 8, wherein the vaccine further comprises an adjuvant suitable for use in a bird which is classified as a member of the Psittaciformes order.
Claim 12
Dependent Claim
22 words
The method of claim 9, wherein the adjuvant is a long chain polydispersed B (1,4) linked mannan polymer interspersed with O-acetylated groups.
Claim 13
Dependent Claim
23 words
The method of claim 9, wherein the adjuvant is a deproteinized highly purified cell wall extract of a non-pathogenic strain of Mycobacterium species.
Claim 14
Dependent Claim
11 words
The method of claim 9, wherein the adjuvant is aluminum hydroxide.
Claim 15
Dependent Claim
24 words
The method of claim 8, wherein the immunogenic amount of the recombinant protein of an avian polyomavirus is between 1.0 mg. and 3 mg.
Claim 16
Dependent Claim
32 words
The method of claim 8, wherein the bird is selected from the group consisting of a macaw, an Amazon parrot, a conure, a cockatoo, a Pionus Parrot, and an African Grey Parrot.
Claim 17
Dependent Claim
16 words
The method of claim 8, further comprising administering at least one booster vaccine to the bird.
Claim 18
Independent Claim
48 words
A method of preventing avian polyomavirus infection in a sensitized bird which is classified as being a member of the Psittaciformes order, comprising administering to the bird a vaccine comprising an immunogenic amount of a recombinant VP1 capsid protein of an avian polyomavirus and a pharmaceutically acceptable carrier.
Claim 19
Independent Claim
48 words
A method of preventing avian polyomavirus infection in a sensitized bird which is classified as being a member of the Psittaciformes order, comprising administering to the bird a vaccine comprising an immunogenic amount of a recombinant VP1 capsid protein of an avian polyomavirus and a pharmaceutically acceptable carrier.